Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib
Case Reports in Hematology · 07.06.2023 · 2023 · 1-5
DOI: 10.1155/2023/9953245 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Hematology, erschienen am 07.06.2023. Verfasst von Vanessa Innao und 3 weiteren Autor:innen. Beteiligte Einrichtung: U.O.C di Ematologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, ARNAS, Garibaldi di Catania, Catania, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grifols.
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is immune-mediated platelet loss due to increased destruction and insufficient production. Treatment guidelines provide for first-line steroid-based therapies followed by thrombopoietin receptor agonists (TPO-RAs) and fostamatinib for chronic ITP. Fostamatinib demonstrated efficacy in phase 3 FIT trials (FIT1 and FIT2) mainly in second-line therapy resulting in the maintenance of stable platelet values. Here, we describe two patients with extremely heterogeneous characteristics that responded to fostamatinib after two and nine previous treatments. Responses were complete with stable platelet counts ≥50,000/μL and without any grade ≥3 adverse reactions. As in the FIT clinical trials, we confirm better responses to fostamatinib when used in the second or third line. However, its use should not be excluded in patients with longer and more complicated drug histories. Given the different mechanism of action of fostamatinib compared to TPO-RAs, it would be interesting to identify predictive factors of responsiveness applicable to all patients.
Autor:innen und Institutionen
- U.O.C di Ematologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, ARNAS, Garibaldi di Catania, Catania, Italy.
ORCID-Profile: Vanessa Innao, Ugo Consoli
Förderung
- Grifols
Zitieren
APA
Innao, V., Calogero, R. D., Lo Presti, F., & Consoli, U. (2023). Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib. Case Reports in Hematology, 2023, 1-5. https://doi.org/10.1155/2023/9953245
Vancouver
Innao V, Calogero RD, Lo Presti F, Consoli U. Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib. Case Reports in Hematology. 2023;2023:1-5. doi:10.1155/2023/9953245
BibTeX
@article{Innao2023,
author = {Innao, Vanessa and Calogero, Rosalba Donatella and Lo Presti, Fabrizio and Consoli, Ugo},
title = {Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib},
journal = {Case Reports in Hematology},
year = {2023},
volume = {2023},
pages = {1--5},
doi = {10.1155/2023/9953245}
}
EUVIMED